NCT02805790View on ClinicalTrials.gov

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 22, 2016

Primary Completion Date

March 10, 2017

Study Completion Date

March 23, 2017

Conditions

Primary Mitochondrial Disease

Interventions

DRUG

Elamipretide

4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously

DRUG

Placebo

4 weeks of treatment with placebo administered once daily subcutaneously

Trial Locations (4)

15224

Children's Hospital of Pittsburg of UPMC, Pittsburgh

44308

Akron Children's Hospital, Akron

92093

University of California, San Diego

02114

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT02805790 - Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study | Biotech Hunter | Biotech Hunter